$150,000 of NATERA INC lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advocacy on importance of FDA's oversight of Laboratory Developed Tests and impact on industry and patients. Advocacy on CMS administrative procedures regarding Date of Service (DOS) for Laboratory testing for patients."
You can find more data on corporate lobbying on Quiver Quantitative.
NTRA Congressional Stock Trading
Members of Congress have traded $NTRA stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 3 times. They made 2 purchases worth up to $30,000 on 09/22, 08/22 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
NTRA Insider Trading Activity
NTRA insiders have traded $NTRA stock on the open market 188 times in the past 6 months. Of those trades, 0 have been purchases and 188 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 23 sales selling 218,361 shares for an estimated $41,942,368.
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 11 sales selling 106,718 shares for an estimated $20,021,243.
- ROELOF BOTHA has made 0 purchases and 11 sales selling 75,000 shares for an estimated $17,708,935.
- HERM ROSENMAN has made 0 purchases and 4 sales selling 48,419 shares for an estimated $11,011,477.
- JONATHAN SHEENA has made 0 purchases and 63 sales selling 56,064 shares for an estimated $10,839,242.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 26 sales selling 28,513 shares for an estimated $5,410,188.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 23 sales selling 18,162 shares for an estimated $2,985,740.
- ROY D. BAYNES has made 0 purchases and 8 sales selling 12,780 shares for an estimated $2,809,688.
- ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 7,116 shares for an estimated $1,520,611.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 6 sales selling 6,279 shares for an estimated $1,034,046.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 7 sales selling 4,775 shares for an estimated $783,289.
- GAIL BOXER MARCUS has made 0 purchases and 3 sales selling 2,618 shares for an estimated $356,637.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NTRA Hedge Fund Activity
We have seen 377 institutional investors add shares of NTRA stock to their portfolio, and 285 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 1,003,129 shares (+9.4%) to their portfolio in Q3 2025, for an estimated $161,473,675
- POINTSTATE CAPITAL LP added 985,963 shares (+702.0%) to their portfolio in Q3 2025, for an estimated $158,710,464
- FRANKLIN RESOURCES INC added 727,366 shares (+37.5%) to their portfolio in Q3 2025, for an estimated $117,084,105
- AQR CAPITAL MANAGEMENT LLC added 673,315 shares (+39.0%) to their portfolio in Q3 2025, for an estimated $108,383,515
- INVESCO LTD. removed 649,956 shares (-34.7%) from their portfolio in Q3 2025, for an estimated $104,623,417
- AMERIPRISE FINANCIAL INC removed 626,686 shares (-67.0%) from their portfolio in Q3 2025, for an estimated $100,877,645
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 616,695 shares (+67.9%) to their portfolio in Q3 2025, for an estimated $99,269,394
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NTRA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- BTIG issued a "Buy" rating on 12/05/2025
- JP Morgan issued a "Overweight" rating on 11/25/2025
- UBS issued a "Buy" rating on 11/18/2025
- Stephens & Co. issued a "Overweight" rating on 11/13/2025
- Piper Sandler issued a "Overweight" rating on 11/11/2025
- Morgan Stanley issued a "Overweight" rating on 11/11/2025
To track analyst ratings and price targets for NTRA, check out Quiver Quantitative's $NTRA forecast page.
NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 13 analysts offer price targets for $NTRA in the last 6 months, with a median target of $260.0.
Here are some recent targets:
- Patrick Donnelly from Citigroup set a target price of $300.0 on 01/07/2026
- Subbu Nambi from Guggenheim set a target price of $270.0 on 01/05/2026
- Kyle Mikson from Canaccord Genuity set a target price of $285.0 on 12/22/2025
- Brandon Couillard from Wells Fargo set a target price of $205.0 on 12/15/2025
- Luke Sergott from Barclays set a target price of $270.0 on 12/15/2025
- Casey Woodring from JP Morgan set a target price of $260.0 on 12/15/2025
- Mark Massaro from BTIG set a target price of $260.0 on 12/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
